Orion Oyj Logo

Orion Oyj

Develops and manufactures human/vet pharma, APIs, and generics for global markets.

ORNAV | HE

Overview

Corporate Details

ISIN(s):
FI0009014377 (+1 more)
LEI:
74370029VAHCXDR7B745
Country:
Finland
Address:
Orionintie 1, FI-02200 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). With a history of over a century, the company focuses on 'building well-being' by translating scientific research into novel therapies and treatments. Orion's research and development efforts are primarily concentrated on specific therapeutic areas, including oncology and pain management. In addition to its portfolio of proprietary drugs, the company also produces generic products and self-care items. Its subsidiary, Fermion, is a key manufacturer of APIs for both Orion and external customers worldwide. Orion also engages in contract manufacturing and the development of diagnostic tests.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 11:00
Quarterly Report
Orion-konsernin osavuosikatsaus tammi-syyskuu 2025
Finnish 22.8 KB
2025-10-28 11:00
Quarterly Report
Orion Group Interim Report January-September 2025
English 22.5 KB
2025-10-24 08:00
Share Issue/Capital Change
49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-10-24 08:00
Share Issue/Capital Change
49,164 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80 802 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80,802 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-20 08:00
Share Issue/Capital Change
337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-08-20 08:00
Share Issue/Capital Change
337,000 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-08 08:30
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Juhani Kankaanpää
Finnish 4.9 KB
2025-08-08 08:30
Director's Dealing
Orion Corporation: Managers' transactions - Juhani Kankaanpää
English 4.8 KB
2025-08-04 15:10
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Satu Ahomäki
Finnish 3.5 KB

Automate Your Workflow. Get a real-time feed of all Orion Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orion Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orion Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America CNTX
Contineum Therapeutics, Inc. Logo
Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.
United States of America CTNM
CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.
United States of America CORT

Talk to a Data Expert

Have a question? We'll get back to you promptly.